Slide 1: On a mission to listen to millions of hearts
On a mission to listen to millions of hearts Acarix Q2 2022 Earnings August 25, 2022
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains, or may be deemed to contain, statements that are not historical facts but forward-looking statements. Such forward-looking statements are based on the current plans, estimates and expectations of Acarix´s management and board based on
Slide 3: We all deserve to know immediately if our chest pain is related to heart disease or not
We all deserve to know immediately if our chest pain is related to heart disease or not
Slide 4: More than 90% of patients with chest pain undergo multiple diagnostic tests for no reason
More than 90% of patients with chest pain undergo multiple diagnostic tests for no reason Challenge • Each day 1 million patients seek medical attention for chest pain related symptoms • Chest pain patients undergo multiple diagnostic tests • Less than 1 out of 10 have coronary artery disease (CAD)
Slide 5: Acarix strategy: Strong commercial focus on creating value in the large US healthcare market
Acarix strategy: Strong commercial focus on creating value in the large US healthcare market 18 million patients per year New CPT III New chest pain guidelines with chest pain – that want reimbursement code and endorsement from immediate results covering CADScor®System clinical leaders Acarix offers
Slide 6: Q2: Continuing to build strong commercial momentum
Q2: Continuing to build strong commercial momentum US: Accelerating growth according to plan • Leadership team established including direct sales team covering NY, CT, NJ, PA, TX • Commercial partners: TN, KY, AL, MS, LA, CA, HI, AK • Key customer wins and increase in ongoing evaluations in Clinics,
Slide 7: Q2: Continuing to build strong commercial momentum
Q2: Continuing to build strong commercial momentum DACH Region • Increased patch utilization in private market • GBA decision based on published FILTER study Market entry in UK • Focus on launch preparations • Rapid Access Chest Pain Clinics Accelerating growth in NORDICS • Progress in key instituti
Slide 8: 2024 Guidance maintained
2024 Guidance maintained • Installed base of 3,000 CADScor®Systems with strong focus on US market • Target revenue >SEK 200 million • Gross margin >80% • Lifetime value (LTV) of CADScor®Systems in US market estimated at $75,000
Slide 9: Our commercial strategy is generating results
Our commercial strategy is generating results Rolling 12-months revenue • Increase from SEK 3.4M in Q2 2021 to SEK 5.2M in Q2 2022 • Increase in revenue due to increased: - sales of patches - average price of CADScor®Systems and disposable patches
Slide 10: Our commercial strategy is generating results
Our commercial strategy is generating results Accumulated use of patches Cumulative patch sales • Cumulative patch sales 19,800 patches, +8,500 vs Q2 2021 • During first half 2022, sales of patches 4,440 (2,790 PY), +59% vs LY
Slide 11: US and patch sales driving increased Gross Margin
US and patch sales driving increased Gross Margin 2,000 Revenue kSEK 1,680 (+91%) Revenue Q2 1,500 • SEK 1 680k (878 PY), +91% vs Q2 PY 878 • DACH Region SEK 919k (838 PY), +10% vs Q2 PY 1,000 • US revenue SEK 594k 500 CADScor®System and patches Q2 • 20 (14 PY) CADScor®Systems, +43% vs Q2 PY 0 • 1,8
Slide 12: Investments and cash position according to plan
Investments and cash position according to plan EBIT Q2 • EBIT SEK -18,383k (-13,093 PY), an increase in spend by 40% vs PY • Increase in operational costs related to building US market and scaling Operation to meet increased sales volumes Cash Position Q2 • Cash and cash equivalents SEK 50,323k vs
Slide 13: Sales and profitability by region
Sales and profitability by region USA (N/A) • Revenue Q2 SEK 594k Region Revenue Revenue Growth Gross Margin Gross Margin • Direct sales and lease orders Q2 2022 Q2 2021 ’21 vs. ’22 Q2 2022 Q2 2021 • Rapid build-up Acarix Sales Organization and Commercial Partners in key states with high sales activ
Slide 14: Q3-Q4 Focus on driving growth
Q3-Q4 Focus on driving growth Continued commercial roll-out US Market • Further expansion and acceleration of commercialization • Positioning : CADScor®System as first line diagnostic aid before any other non-invasive testing is performed in symptomatic patients • Reimbursement: CPT III code adoptio
Slide 15: Communication and Events 2022
Communication and Events 2022 1. Quarterly Reports (With webcast presentation) - Q3 November 10, 2022 - Q4 February 16, 2023 2. New Newsletter Mid-quarter update 3. Press Releases and News - Press Releases on key developments - Posted on new Website, LinkedIn 4. New Website www.acarix.com/news/ 5. S
Slide 16: Q & A Visit us at www.acarix.com
Q&A Visit us at www.acarix.com